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doi:10.1016/j.ejvs.2009.03.016Abstract Objectives: Botulinum toxin injection effectively treats axillary hyperhidrosis.
Durability estimates of 3e14 months, based on self re-referral may overestimate duration.
Our objective was to determine treatment durability by active follow-up of patients.
Design: Audit of current practice.
Materials and methods: Patients presenting with severe primary axillary hyperhidrosis were
actively followed up for 24 months after intradermal injections of Botulinum Toxin A (Dysport
120 units/axilla). A 10-point Likert Scale (1Zworst imaginable symptoms, 10Z absolute reso-
lution) and the Hyperhidrosis Disease Severity Score (HDSS) were used at 1 day and 3, 6, 12 and
24 months. We offered re-treatment when symptoms returned to the pre-intervention state.
Results: We treated 45 patients with a mean age of 29 (15e49) years of whom 36 (78%) were
women. The median pre-treatment Likert score (i.q.r.) of 3 (2e3) improved to 10 (10e10) on
day 1. Scores at 3 (nZ 44), 6 (nZ 43) and 12 (nZ 39) months were 10 (10e10), 8 (7.5e10),
and 7 (5e8) respectively. The median 24-month score was 3 (3e6) for 35 patients, including
11 patients with scores 6 who have not required re-treatment. HDSS scores followed a similar
pattern.
Conclusions: Axillary botulinum toxin treatment is durable. Patients experience gradual return
of symptoms between 6 and 24 months. A minority do not require re-treatment at this time.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Botulinum toxin A was first described for use in axillary
hyperhidrosis in 19961 and has been licensed for use in the
UK since 2001. The safety and efficacy of this treatment
have been well documented.2,3 Initial reports were of short
duration treatments; further studies have been done over1905 760752; fax: þ44 1905
kye@worcsacute.nhs.uk
ty for Vascular Surgery. Publishea longer time period to assess durability.4e7 However, these
papers often use self-referral for re-treatment to deter-
mine the symptom-free interval, and hence may be unre-
liable. Patients may move away, seek treatment elsewhere,
or be unwilling to undergo the same treatment again and
therefore not re-attend. Barriers in access to outpatient
appointments result in delays in patients being seen by
physicians and may further lengthen the apparent
symptom-free intervals. Our aim was to actively follow-up
patients after treatment with botulinum toxin A tod by Elsevier Ltd. All rights reserved.
Table 1 Durability of botulinum toxin A in axillary
hyperhidrosis determined by patient symptom scores.
nZMinimum1st
Quartile
Median 3rd
Quartile
Maximum
Pre-
treatment
45 2 2 3 3 6
Day 1 45 3 10 10 10 10
3 months 44 3 10 10 10 10
6 months 43 3 7.5 8 10 10
12 months 39 3 5 7 8 10
24 months 35 3 3 3 6 8
Table showing the median, interquartile range, and range of
Likert symptom scores (1Zworst imaginable symptoms,
10Z absolute resolution) with the duration of follow-up.
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In this way we hoped to either confirm or refute previous
findings.
Materials and Methods
Patients with severe primary axillary hyperhidrosis were
recruited for treatment with intradermal injection of
botulinum toxin A. They underwent standard pre-treatment
counselling of risks, benefits and alternatives to treatment.
Those patients who agreed to treatment were treated in
a day case setting after application of topical local anaes-
thesia (tetracaine).8 Bilateral intradermal injections of
botulinum toxin A (120 units/axilla, Dysport (Ipsen,
Slough, UK)) were given. Patients were then followed up for
a 24-month period, with interviews on day 1 and subse-
quently 3, 6, 12 and 24 months post-procedure. Patients
were invited to self-refer if their symptoms recurred
between appointments, and were re-treated once their
symptoms in either axilla had returned to pre-treatment
levels. At pre-treatment interview and subsequent follow-
up appointments, patients were asked to rate their symp-
toms both on a Likert scale, ranging from 1 to 10 (1Zworst
imaginable symptoms, 10Z absolute resolution)9 and the
Hyperhidrosis Disease Severity Scale (HDSS).10 Re-treated
patients were also followed up at similar time intervals and
had their symptoms rated as previously. To avoid showing
the biased and favourable result that would be otherwise
introduced by patients undergoing re-treatment, we have
kept them at their lowest score before the second treat-
ment when calculating outcomes up to the 24-month
follow-up period.
Results
Forty-five patients were treated, of whom 36 were women
(78%). Their mean age was 29 with a range of 15e49 years.
Fig. 1 graphically illustrates the Likert scores obtained pre-
treatment and at follow-up interval. The correspondingMedian, Range and Interq
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Figure 1 Box and Whisker plot showing the median (þ), inte
(1Zworst imaginable symptoms, 10Z absolute resolution) with thdata is shown in Table 1. Their median and interquartile
range (i.q.r.) pre-treatment score of 3 (2e3) improved to 10
(10e10) on day 1. One patient failed to respond to treat-
ment and her score of 3 is retained throughout the study
period. Incidentally this patient underwent a further
treatment, and again failed to respond.
Subsequent median scores obtained at 3 (nZ 44), 6
(nZ 43) and 12 (nZ 39) months were 10 (10e10), 8 (7.5e10)
and 7 (5e8), respectively. At 6 months, five patients
had returned to their pre-treatment scores, and at 12
months a further five patients had reached their pre-
treatment scores.
At 24 months the median score had returned to 3 (3e6)
for 33 patients. However, 11 of these still scored 6 and
had not required re-treatment. The corresponding HDSS
scores are shown in Fig. 2 along with the data in Table 2.
Using the return to pre-treatment scores to define non-
survival we have plotted our overall results, including
outcomes beyond 24 months, on a KaplaneMeier survival
curve; this is shown in Fig. 3.
Twenty-one patients have undergone re-treatment.
Their median (i.q.r.) pre-treatment scores were 3 (3e3)
which improved to 10 (10e10) on day 1. Three monthsuartile Range of Likert Scores
er initial treatment
6 months
(n=43)
12 months
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24 months
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rquartile range (,) and range (I) of Likert symptom scores
e duration of follow-up.
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Figure 2 Box and Whisker plot showing the median (þ), interquartile range (,) and range (I) of Hyperhidrosis Disease Severity
Scores (HDSS) with the duration of follow-up.
190 C.E. Moffat et al.following the re-treatment, their scores were 10 (10e10)
and at 6 months the scores were 9 (8e10) for 16 patients.
Discussion
There are few specific studies on the durability of botu-
linum toxin A treatment for axillary hyperhidrosis. James
et al. treated 104 patients with botulinum toxin A (Dysport)
and invited patients to self-refer when they required
further treatment. They found that 66% of their patients
returned for a second treatment at 6 months.6 Absar
treating 52 patients quoted a mean symptom-free period of
5.97 months (3e14 months) based on requests by patients
for re-treatment.7 Whatling and Collin reported a mean
duration of 9 months of treatment in 16 of their patients.4Table 2 Durability of botulinum toxin A in axillary
hyperhidrosis determined by Hyperhidrosis Disease Severity
Scale (HDSS).
nZMinimum1st
Quartile
Median3rd
Quartile
Maximum
Pre-
treatment
45 3 4 4 4 4
Day 1 45 1 1 1 1 4
3 months 44 1 1 1 1 4
6 months 43 1 1 1 1 4
12 months 39 1 1 2 3 4
24 months 35 1 2 4 4 4
Table showing the median, interquartile range and range of
HDSS scores with the duration of follow-up. HDSS 1ZMy
underarm sweating is never noticeable and never interferes
with my daily activities. HDSS 2ZMy underarm sweating is
tolerable but sometimes interferes with my daily activities.
HDSS 3ZMy underarm sweating is barely tolerable and
frequently interferes with my daily activities. HDSS 4ZMy
underarm sweating is intolerable and always interferes with my
daily activities.Naumann and Hamm quoted a mean duration of benefit of
7 months in a review article,11 based on unpublished data
that was presented.5 These data were from a continuation
study following up 207 patients from an earlier randomised
controlled trial by monthly telephone calls for a further 12
months. In a more recent study Lowe et al. followed up
patients (telephone contact or patient visit) at day 7, for
a total of 52 weeks. They found median durations of effect
of 197 and 205 days with two different doses of botulinum
toxin A.3
We have found botulinum toxin A to be efficacious in the
treatment of primary hyperhidrosis. The majority of
patients achieved absolute resolution of symptoms within
24 h, which was sustained for at least 3 months. By 6
months, 25 out of 40 patients (62%) had started to experi-
ence some degree of symptom-return but only five patients
(12%) had returned to their pre-treatment scores and were
re-treated. There was a further decrease in scores atSurvival Plot (PL estimates)
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Figure 3 KaplaneMeier survival plot showing patients
treated with botulinum toxin A whose symptoms have not
reached their pre-treatment levels and have not required
re-treatment as event survivors plotted against time in months.
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treatment. However, even at this time 18 patients out of
the 33 (54%) continued to be relatively symptom-free and
did not request re-treatment. For the 21 patients reaching
24 months, the median score had returned to the median
pre-treatment score(3). However, their absolute range was
3e8. A few patients still had not required re-treatment well
beyond 24 months.
By comparison with previous studies, relatively few of
our patients had been re-treated at 6 months. This differ-
ence cannot be explained in terms of botulinum toxin type
or treatment technique. The most likely explanation for
our prolonged durability is our advice to patients at the
outset that we would use ‘return to pre-treatment
symptom severity’ as our criteria for re-treatment. The
previous studies that used self-referral may have re-
treated patients at the first return of, perhaps milder,
symptoms.
One limitation of following up patients at fixed intervals
is that if their symptoms return soon after a planned
review, this would not be apparent in the data until the
next fixed interval. This potential source of error was
avoided in this study by allowing self re-referral in the
intervals in between their fixed appointments.
This study represents a more comprehensive picture of
treatment durability and symptom-return, compared to
previous reports. Following botulinum toxin A treatment for
axillary hyperhidrosis, a minority of patients experience
return of symptoms within 6 months; however, most will
become symptomatic again between 6 and 12 months. A
small group of patients continue to be relatively symptom-
free for as long as 24 months. Our findings are consistent
with those of previous reports, and support the use of self-
referral as an effective method of managing patients who
have had botulinum toxin treatment for primary axillary
hyperhidrosis.Conflict of Interest/Funding
None.Acknowledgements
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